Azithromycin ophthalmic solution, 1% + Placebo

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Blepharitis

Conditions

Blepharitis

Trial Timeline

Apr 1, 2009 → Jan 1, 2010

NCT ID

NCT00892970

About Azithromycin ophthalmic solution, 1% + Placebo

Azithromycin ophthalmic solution, 1% + Placebo is a phase 2 stage product being developed by Merck for Blepharitis. The current trial status is completed. This product is registered under clinical trial identifier NCT00892970. Target conditions include Blepharitis.

What happened to similar drugs?

5 of 10 similar drugs in Blepharitis were approved

Approved (5) Terminated (1) Active (4)

✅Lotilaner ophthalmic solution, 0.25% + Vehicle controlTarsus PharmaceuticalsApproved

🔄TP-03 + TP-03 VehicleTarsus PharmaceuticalsPhase 3

🔄Lotilaner + Vehicle ControlLianBioPhase 3

🔄ISV-305Sun PharmaceuticalPhase 3

🔄ISV-502 (1.0% azithromycin and 0.1% dexamethasone combined) + Azasite + DexamethasoneSun PharmaceuticalPhase 3

✅AzaSite®MerckApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT01014078	Approved	Completed	Oct 1, 2009	Mar 1, 2010	Dry Eye Disease
NCT00894530	Phase 2	Completed	May 1, 2009	Dec 1, 2009	Blepharitis
NCT00892970	Phase 2	Completed	Apr 1, 2009	Jan 1, 2010	Blepharitis

Competing Products

15 competing products in Blepharitis

See all competitors

Product	Company	Stage	Hype Score
Lotilaner ophthalmic solution, 0.25% + Vehicle control	Tarsus Pharmaceuticals	Approved	37
TP-03 + TP-03 Vehicle	Tarsus Pharmaceuticals	Phase 3	34
TP-03, 0.25% + TP-03 Vehicle	Tarsus Pharmaceuticals	Phase 2/3	32
Lotilaner + Vehicle Control	LianBio	Phase 3	30
ISV-305	Sun Pharmaceutical	Phase 3	40
ISV-502 (1.0% azithromycin and 0.1% dexamethasone combined) + Azasite + Dexamethasone	Sun Pharmaceutical	Phase 3	40
AzaSite®	Merck	Approved	43
AzaSite®	Merck	Approved	43
AzaSite®	Merck	Approved	43
AzaSite®	Merck	Approved	43
Azithromycin ophthalmic solution, 1% + Placebo	Merck	Phase 2	35
Azithromycin ophthalmic solution, 1% + Vehicle	Merck	Phase 2	27
Pimecrolimus 0.3% Ophthalmic Ointment + Placebo Ophthalmic Ointment	Viatris	Phase 3	29
GLK-321 low dose BID + GLK-321 mid dose BID + GLK-321 high dose BID + GLK-321 high dose QD + Placebo BID	Glaukos	Phase 2	39
KPI-121 + Vehicle	Kala Pharmaceuticals	Phase 2	25